Key Highlights

• Bluejay fell nearly 23% on June 24, continuing a sharp decline driven by dilutive financing pressure.

• The company closed two equity raises totalling more than $32 million between June 2 and June 5.

• Both raises were priced at-the-market, creating significant selling pressure relative to the float.

• Cash heading into June stood at approximately $3.7 million, explaining the need for the capital raises.

Bluejay Diagnostics (NASDAQ:BJDX), which is advancing its Symphony IL-6 sepsis diagnostic platform toward a 510(k) FDA submission, fell nearly 23% on June 24 as the combined dilutive weight of two recent capital raises continued to generate selling pressure against a float of approximately one million shares.

The company closed an $8.5 million private placement in early June, followed by a further transaction valued at up to $23.7 million between June 2 and June 5, with both deals priced at-the-market. The scale of the combined capital raise relative to Bluejay's float creates a structural overhang in which newly issued shares are likely to be sold by placement participants seeking to exit at or near the issuance price, irrespective of the company's clinical progress.

The financing was necessitated by a cash position of approximately $3.7 million heading into June, a level that would have been insufficient to fund continued clinical operations. The capital raised extends the company's runway, but the terms under which it was secured have imposed a significant short-term cost on existing shareholders through dilution.

Clinical enrollment in the SYMON-II trial, Bluejay's pivotal study for the Symphony IL-6 platform, approached its 750-patient target around the time of the raises, suggesting the company is progressing toward its regulatory milestone even as the share price comes under pressure from financing mechanics.